---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-104145"
form_type: "8-K"
ticker: "ALMS"
cik: "0001847367"
company_name: "ALUMIS INC."
filed_at: "2026-09-01T12:30:46+00:00"
generated_at: "2026-09-01T12:35:09.907762+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Alumis LUMUS Phase 2b misses primary endpoint in SLE; IFNGS-high subgroup shows robust responses

## Summary
- LUMUS Phase 2b (n=408) did not meet primary endpoint BICLA at Week 48 in overall SLE population.
- Prespecified IFNGS-high subgroup showed robust responses on BICLA, CLASI-50, SRI-4, and LLDAS.
- Dose-dependent target engagement with maximal suppression at 40mg BID; no new safety signals observed.
- Alumis plans regulatory engagement to discuss Phase 3 development for envudeucitinib in SLE.
- NDA submission for envudeucitinib in moderate-to-severe plaque psoriasis remains on track for 4Q 2026.

## SEC filing metadata
- accession: 0001104659-26-104145
- form_type: 8-K
- ticker: ALMS
- cik: 0001847367
- company_name: ALUMIS INC.
- filed_at: 2026-09-01T12:30:46+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847367/000110465926104145/0001104659-26-104145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847367/000110465926104145/tm2624540d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-104145
- JSON: https://secwatch.observer/filing/0001104659-26-104145.json
- Plain text: https://secwatch.observer/filing/0001104659-26-104145.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.